Why Fresenius SE KGaA (XTRA:FRE) is back in focus after Q2 earnings
Fresenius SE KGaA (XTRA:FRE) has moved back onto investors’ radar after raising its full year core EPS growth guidance to 10% to 15% alongside Q2 results that outpaced previous performance metrics.
The company reported Q2 2026 sales of €5,945 million compared with €5,650 million a year earlier, while net income was €382 million versus €330 million. Basic earnings per share from continuing operations reached €0.68 compared with €0.58.
See our latest analysis for Fresenius SE KGaA.
Against this earnings backdrop, Fresenius SE KGaA’s share price has responded positively in recent weeks, with a 1 day share price return of 5.16% and a 90 day share price return of 14.51%, while the 1 year total shareholder return of 15.15% and 3 year total shareholder return of 71.21% point to momentum that has built over time despite a modest decline of 2.26% in the year to date share price return.
If Fresenius SE KGaA’s renewed earnings momentum has your attention, it can be useful to see what else is working in healthcare right now. Take the next step and review 129 healthcare AI stocks
After Fresenius SE KGaA’s sharp post earnings move, the puzzle now is whether that strength already reflects the good news or if the current price still leaves room before waiting for a pullback makes more sense.
Most Popular Narrative: 14.9% Undervalued
On the most followed narrative, Fresenius SE KGaA’s fair value of €54.79 sits above the last close at €46.65, which puts fresh attention on what is built into that gap.
Ongoing portfolio optimization and business restructuring, with a focus on streamlining core healthcare services and divesting non core assets, is improving operational focus, capital efficiency, and leading to margin expansion, demonstrated by a 13% CAGR in Kabi EBIT over the last two years. (Likely to impact EBIT margins and net earnings.)
Want to see what sits behind that Kabi margin story and the fair value of €54.79? The narrative leans on steady revenue growth, fatter margins and a richer earnings multiple that needs to hold up over time.
Result: Fair Value of €54.79 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Fresenius SE KGaA still faces pressure from cost inflation and tighter healthcare budgets, which could squeeze margins and challenge the current undervaluation story.
Find out about the key risks to this Fresenius SE KGaA narrative.
Next Steps
This mix of optimism and concern around Fresenius SE KGaA means the story is still developing, so move quickly to check the full context and weigh both sides through the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Fresenius SE KGaA?
If Fresenius SE KGaA has sharpened your interest in healthcare and beyond, it makes sense to widen your search and see what other opportunities currently fit your investing style.
- Target reliable cash generators by screening for companies with resilient earnings and healthy payouts through 445 dividend fortresses
- Spot potential value opportunities early by filtering for companies that combine quality fundamentals with attractive pricing using the 249 high quality undervalued stocks
- Prioritise resilience by focusing on businesses with strong finances and low risk scores via the 297 resilient stocks with low risk scores
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com